Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Breast Neoplasms 17Triple Negative Breast Neoplasms 9Urinary Bladder Neoplasms 1Resectable HER2-positive Breast Cancer 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplastic Cells, Circulating 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Hormone Receptor Positive HER-2 Negative Breast Cancer 1HR-positive,HER2-negative Breast Cancer 1HR+/HER2- Breast Cancer 1HER2-negative Early Breast Cancer 1HER2-negative Breast Cancer 1HER2 Positive Early Breast Cancer 1Carcinoma, Ovarian Epithelial 1Carcinoma, Adenoid Cystic 1

Interventions

Dexamethasone 87daratumumab 49Lenalidomide 49pomalidomide 33Bortezomib 32Cyclophosphamide 31carfilzomib 25Calcium Dobesilate 21talquetamab 19fludarabine 18isatuximab 16iberdomide 16Magnetic Resonance Spectroscopy 16Specimen Handling 15Biopsy 14selinexor 12Melphalan 11belantamab mafodotin 10dexamethasone acetate 9dexamethasone 21-phosphate 8elotuzumab 7auricularum 7venetoclax 6tocilizumab 5fludarabine phosphate 5X-Rays 5Blood Specimen Collection 5ruxolitinib 4Methylprednisolone 4Injections 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Multiple Myeloma × Epirubicin × Clear all
NCT06140966 2025-04-16

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Recruiting
54 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡